Related Experiment Video
Updated: May 7, 2026

Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells
Published on: March 22, 2024
Osteoclast differentiation inhibitors: a patent review (2008 - 2012)
Seong Hwan Kim1, Seong-Hee Moon
1Korea Research Institute of Chemical Technology, Pharmacology Research Center, Division of Drug Discovery Research, Laboratory of Translational Therapeutics , P.O.Box 107, Yuseong-gu, Daejeon 305-600 , Republic of Korea +82 42 860 7687 ; hwan@krict.re.kr.
Introduction:
Mononuclear macrophage/monocyte-lineage hematopoietic precursors differentiate into multinucleated osteoclasts. Abnormally increased numbers and/or overactivation of osteoclasts can lead to bone loss. Therefore, pharmaceutical inhibition of osteoclast differentiation is one therapeutic strategy for mitigating the occurrence of bone loss-associated disorders and related fractures.
Areas Covered:
This review surveys the patents and patent applications from 2008 to 2012 that are related to inventions of therapeutics and/or methods for inhibiting osteoclast differentiation.
Expert Opinion:
Over the past 20 years, the identification and validation of signaling molecules involved in osteoclast differentiation has led to a better understanding of the molecular mechanism, and to the development of new therapeutic agents for treating bone loss-associated disorders. Since 2008, 34 WO patents or patent applications have been filed that relate to inventions of therapeutics and/or methods for chemical-based, natural product-based, or biological-based inhibitors of osteoclast differentiation. Here, analysis of these patents and patent applications is presented, and summarize the disclosed osteoclast differentiation-inhibiting target molecules. This report can support further advances in the development of anti-osteoclastogenic therapeutics for bone loss-associated disorders, including osteoporosis, rheumatoid arthritis, Paget's disease, periodontal disease, osteosarcoma, and cancer bone metastasis.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Products: Biologics, Biosimilars and Interchangeables
Forced Transdifferentiation
Artificial transdifferentiation occurs...
iPS Cell Differentiation
Inhibition of Cdk Activity
Osteoclasts in Bone Remodeling
